Tumor-specific targeting of pancreatic cancer with shiga toxin B-subunit

Molecular Cancer Therapeutics

Volumn 10, Issue 10, 2011, Pages 1918-1928

  Maak, Matthias ^a   Nitsche, Ulrich ^a   Keller, Larissa ^a   Wolf, Petra ^a   Sarr, Marianne ^c,d   Thiebaud, Marine ^c,d   Rosenberg, Robert ^a   Langer, Rupert ^b   Kleeff, Jor̈g ^a   Friess, Helmut ^a   Johannes, Ludger ^c,d   Janssen, Klaus Peter ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUT CURIE   (France)

^d INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; IRINOTECAN; SHIGA TOXIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; FEMALE; GENE TARGETING; GOLGI COMPLEX; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; THIN LAYER CHROMATOGRAPHY; TREATMENT OUTCOME; TUMOR CELL; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CAMPTOTHECIN; CELL LINE, TUMOR; FEMALE; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SHIGA TOXINS; TOPOISOMERASE I INHIBITORS;

EID: 80053948975     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0006     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Brus C, Saif MW. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP 2010;11:321-3.
3. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-7. (Pubitemid 46954645)
4. Kovbasnjuk O, Mourtazina R, Baibakov B, Wang T, Elowsky C, Choti MA, et al. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci U S A 2005;102:19087-92. (Pubitemid 43049570)
5. Falguieres T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon MF, et al. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther 2008;7:2498-508.
6. Janssen KP, Vignjevic D, Boisgard R, Falguières T, Bousquet G, Decaudin D, et al. In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. Cancer Res 2006;66:7230-6. (Pubitemid 44197703)
7. Johannes L, Romer W. Shiga toxins-from cell biology to biomedical applications. Nat Rev Microbiol 2010;8:105-16.
8. Lingwood CA, Binnington B, Manis A, Branch DR. Globotriaosyl ceramide receptor function - where membrane structure and pathology intersect. FEBS Lett 2010;584:1879-86.
9. Muthing J, Schweppe CH, Karch H, Friedrich AW. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb Haemost 2009;101:252-64.
10. Sandvig K, Torgersen ML, Engedal N, Skotland T, Iversen TG. Protein toxins from plants and bacteria: probes for intracellular transport and tools in medicine. FEBS Lett 2010;584:2626-34.
11. Bast DJ, Brunton JL, Karmali MA, Richardson SE. Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits. Infect Immun 1997;65:2019-28. (Pubitemid 27237273)
12. Chart H, Law D, Rowe B, Acheson DW. Patients with haemolytic uraemic syndrome caused by Escherichia coli O157: absence of antibodies to Vero cytotoxin 1 (VT1) or VT2. J Clin Pathol 1993;46: 1053-4. (Pubitemid 23349242)
13. Distler U, Souady J, Hulsewig M, Drmić-Hofman I, Haier J, Friedrich AW, et al. Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS One 2009;4:e6813.
14. Arab S, Rutka J, Lingwood C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol Res 1999;11:33-9.
15. El Alaoui A, Schmidt F, Amessou M, Sarr M, Decaudin D, Florent JC, et al. Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug. Angew Chem Int Ed Engl 2007;46:6469-72. (Pubitemid 47340174)
16. Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, et al. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine 2010;6:478-85.
17. Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 2008;14: 1888-96. (Pubitemid 351469476)
18. Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, et al. Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer. Cancer J 2007;13:257-62.
19. de la Fouchardiere C, Negrier S, Labrosse H, Martel Lafay I, Desseigne F, Méeus P, et al. Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010;77:409-13.
20. Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G. Irinotecan plus bolus/infusional 5-fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 2010;33:461-4.
21. Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 2003;21:19-22. (Pubitemid 37127470)
22. Johannes L, Tenza D, Antony C, Goud B. Retrograde transport of KDEL-bearing B-fragment of Shiga toxin. J Biol Chem 1997;272: 19554-61. (Pubitemid 27337757)
23. Mallard F, Johannes L. Shiga toxin B-subunit as a tool to study retrograde transport. Methods Mol Med 2003;73:209-20.
24. Falguieres T, Mallard F, Baron C, Hanau D, Lingwood C, Goud B, et al. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol Biol Cell 2001;12:2453-68. (Pubitemid 33051968)
25. Pellizzari A, Pang H, Lingwood CA. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 1992;31:1363-70.
26. Falguieres T, Roemer W, Amessou M, Afonso C, Wolf C, Tabet JC, et al. Functionally different pools of Shiga toxin receptor, globotriaosyl ceramide, in HeLa cells. FEBS J 2006;273:5205-18. (Pubitemid 44673308)
27. Schuller S, Heuschkel R, Torrente F, Kaper JB, Phillips AD. Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect 2007;9:35-9. (Pubitemid 46149416)
28. Bast DJ, Sandhu J, Hozumi N, Barber B, Brunton J. Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30. Infect Immun 1997;65:2978-82. (Pubitemid 27264134)
29. Hakomori SI. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj J 2000;17:143-51.
30. Ono M, Hakomori S. Glycosylation defining cancer cell motility and invasiveness. Glycoconj J 2004;20:71-8. (Pubitemid 38392180)
31. Johansson D, Andersson C, Moharer J, Johansson A, Behnam- Motlagh P. Cisplatin-induced expression of Gb3 enables verotoxin- 1 treatment of cisplatin resistance in malignant pleural mesothelioma cells. Br J Cancer 2010;102:383-91.
32. De Rosa MF, Ackerley C, Wang B, Ito S, Clarke DM, Lingwood C. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog. J Biol Chem 2008;283:4501-11.
33. Lingwood CA, Khine AA, Arab S. Globotriaosyl ceramide (Gb3) expression in human tumour cells: intracellular trafficking defines a new retrograde transport pathway from the cell surface to the nucleus, which correlates with sensitivity to verotoxin. Acta Biochim Pol 1998;45:351-9. (Pubitemid 128480895)
34. Miyamoto Y, Iimura M, Kaper JB, Torres AG, Kagnoff MF. Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. Cell Microbiol 2006;8: 869-79.
35. Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993;268:15484-8. (Pubitemid 23222039)
36. Heath-Engel HM, Lingwood CA. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker. Angiogenesis 2003;6:129-41. (Pubitemid 38173864)
37. Lingwood CA. Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineoplasia. Biosci Rep 1999;19:345-54. (Pubitemid 30169335)
38. Viel T, Dransart E, Nemati F, Henry E, Theze B, Decaudin D, et al. In vivo tumor targeting by the B-subunit of shiga toxin. Mol Imaging 2008;7:239-47.
39. Ebrahimnejad P, Dinarvand R, Sajadi SA, Atyabi F, Ramezani F, Jaafari MR. Preparation and characterization of poly lactide-co-glycolide nanoparticles of SN-38. PDA J Pharm Sci Technol 2009;63: 512-20.
40. Kunii R, Onishi H, Machida Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Biopharm 2007;67:9-17. (Pubitemid 46991341)
41. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 2004;270:93-107. (Pubitemid 38077091)
42. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 2006;66:10048-56. (Pubitemid 44672058)
43. Nakajima TE, Yasunaga M, Kano Y, Koizumi F, Kato K, Hamaguchi T, et al. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5- fluorouracil. Int J Cancer 2008;122:2148-53. (Pubitemid 351441208)
44. Kaye SA, Louise CB, Boyd B, Lingwood CA, Obrig TG. Shiga toxinassociated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 1993;61:3886-91. (Pubitemid 23260063)
45. Taguchi T, Uchida H, Kiyokawa N, Mori T, Sato N, Horie H, et al. Verotoxins induce apoptosis in human renal tubular epithelium derived cells. Kidney Int 1998;53:1681-8. (Pubitemid 28243752)
46. Ergonul Z, Clayton F, Fogo AB, Kohan DE. Shigatoxin-1 binding and receptor expression in human kidneys do not change with age. Pediatr Nephrol 2003;18:246-53. (Pubitemid 36790049)
47. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997;33:S18-22.
48. Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to singleagent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007;18:1652-9. (Pubitemid 47514482)
49. Klapdor R, Fenner C. Irinotecan(Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer. Anticancer Res 2000;20: 5209-12. (Pubitemid 32319108)
50. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009;101:1658-63.